Results 241 to 250 of about 59,932 (250)

Remdesivir in The Treatment of COVID-19.

The American Journal of Nursing, 2021
According to this study: The antiviral remdesivir is superior to placebo in the treatment of patients hospitalized with COVID-19.A variety of therapeutic approaches are needed to continue to improve outcomes in COVID-19 patients.
K. Rosenberg
semanticscholar   +1 more source

Lower Mortality Risk Associated With Remdesivir + Dexamethasone Versus Dexamethasone Alone for the Treatment of Patients Hospitalized for COVID-19

Clinical Infectious Diseases
Background Treatment guidelines were developed early in the pandemic when much about coronavirus disease 2019 (COVID-19) was unknown. Given the evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), real-world data can provide ...
E. Mozaffari, Aastha Chandak, Robert L Gottlieb, Chidinma Chima-Melton, Mark Berry, Thomas F. Oppelt, Jason F. Okulicz, Alpesh N Amin, T. Welte, Paul E Sax, Andre C. Kalil   +10 more
semanticscholar   +1 more source

Real-world evaluation of early remdesivir in high-risk COVID-19 outpatients during Omicron including BQ.1/BQ.1.1/XBB.1.5

BMC Infectious Diseases
Background A trial performed among unvaccinated, high-risk outpatients with COVID-19 during the delta period showed remdesivir reduced hospitalization. We used our real-world data platform to determine the effectiveness of remdesivir on reducing 28-day ...
Kyle C Molina, Brandon J. Webb, Victoria Kennerley, L. Beaty, Tellen D. Bennett, N. Carlson, D. Mayer, Jennifer L. Peers, S. Russell, Matthew K. Wynia, Neil R. Aggarwal, A. Ginde   +11 more
semanticscholar   +1 more source

SARS-CoV-2 resistance analyses from the Phase 3 PINETREE study of remdesivir treatment in nonhospitalized participants

Antimicrobial Agents and Chemotherapy
Remdesivir inhibits the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp; Nsp12). Here, we conducted viral resistance analyses from the Phase 3 PINETREE trial of remdesivir in nonhospitalized participants at risk of severe COVID-19.
Lauren Rodriguez, Hery W. Lee, Jiani Li, Ross Martin, Dong Han, Simin Xu, Jasmine Moshiri, Nadine Peinovich, Gregory Camus, Jason K. Perry, Robert H. Hyland, D. Porter, Mazin Abdelghany, Matthias Götte, C. Hedskog   +14 more
semanticscholar   +1 more source

Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir

Science, 2020
Wanchao Yin, Chunyou Mao, Xiaodong Luan
exaly  

De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report

Nature Communications, 2022
Shiv K Gandhi, Jonathan Klein, Alexander J Robertson   +2 more
exaly  

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

New England Journal of Medicine, 2021
Andre C Kalil, Aneesh K Mehta, Vincent C Marconi   +2 more
exaly  

Remdesivir against COVID-19 and Other Viral Diseases

Clinical Microbiology Reviews, 2020
Jakob J Malin, Isabelle Suárez, Priv-Doz Dr Dr Jan Rybniker   +2 more
exaly  

Comparative effectiveness of combination therapy with nirmatrelvir-ritonavir and remdesivir versus monotherapy with remdesivir or nirmatrelvir-ritonavir in patients hospitalised with COVID-19: a target trial emulation study.

Lancet. Infectious Diseases (Print)
M. Choi, E. Wan, I. C. K. Wong, E. Chan, Wing-Ming Chu, A. Tam, Kwok-Yung Yuen, I. F. Hung   +7 more
semanticscholar   +1 more source

Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge

Science Translational Medicine, 2019
Michael K Lo, Friederike Feldmann, Roy Bannister   +2 more
exaly